Denali Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Denali Therapeutics

06/08/2024 13:00

* Denali Therapeutics Inc  DNLI.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of $1.30.  The mean expectation of sixteen analysts for the
quarter was for a loss of 69 cents per share. Wall Street
expected results to range from -85 cents to -43 cents per share.
    * Reported revenue was zero​; analysts expected $15.49
million. 
    * Denali Therapeutics Inc's reported EPS for the quarter was
a
loss of 59 cents​.
    * The company reported a quarterly loss of $99.03 million.
    * Denali Therapeutics Inc shares had fallen by 6.8% this
quarter and gained 0.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.6%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Denali
Therapeutics Inc is $35.00 
This summary was machine generated from LSEG data August 6 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.69          -0.59          Beat
 Mar. 31 2024      -0.70          -0.78          Missed
 Dec. 31 2023      -0.80          -0.86          Missed
 Sep. 30 2023      -0.80          -0.72          Beat